ATE110739T1 - Tuftsin-analoge und impfstoffe, die diese analoge als adjuvantien enthalten. - Google Patents

Tuftsin-analoge und impfstoffe, die diese analoge als adjuvantien enthalten.

Info

Publication number
ATE110739T1
ATE110739T1 AT89201371T AT89201371T ATE110739T1 AT E110739 T1 ATE110739 T1 AT E110739T1 AT 89201371 T AT89201371 T AT 89201371T AT 89201371 T AT89201371 T AT 89201371T AT E110739 T1 ATE110739 T1 AT E110739T1
Authority
AT
Austria
Prior art keywords
analogs
tuftsin
adjuvants
vaccines
vaccines containing
Prior art date
Application number
AT89201371T
Other languages
English (en)
Inventor
Luciano Nencioni
Piero Pileri
Samuele Peppoloni
Sergio Silvestri
Original Assignee
Sclavo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sclavo Spa filed Critical Sclavo Spa
Application granted granted Critical
Publication of ATE110739T1 publication Critical patent/ATE110739T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
AT89201371T 1989-02-10 1989-05-30 Tuftsin-analoge und impfstoffe, die diese analoge als adjuvantien enthalten. ATE110739T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8919408A IT1230712B (it) 1989-02-10 1989-02-10 Composizione per vaccini

Publications (1)

Publication Number Publication Date
ATE110739T1 true ATE110739T1 (de) 1994-09-15

Family

ID=11157520

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89201371T ATE110739T1 (de) 1989-02-10 1989-05-30 Tuftsin-analoge und impfstoffe, die diese analoge als adjuvantien enthalten.

Country Status (8)

Country Link
US (1) US4957736A (de)
EP (1) EP0392095B1 (de)
JP (1) JPH02215797A (de)
AT (1) ATE110739T1 (de)
CA (1) CA1338318C (de)
DE (1) DE68917907T2 (de)
ES (1) ES2058473T3 (de)
IT (1) IT1230712B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569745A (en) * 1994-02-25 1996-10-29 Resolution Pharmaceuticals Inc. Peptide-Chelator conjugates
US5662885A (en) * 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
US5741680A (en) * 1996-09-03 1998-04-21 Cera Products, Inc. Buffer composition base and method of formulation for oral vaccine delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
US4353823A (en) * 1981-09-01 1982-10-12 Chipens Gunar I Synthetic analog of tuftisin
US4390528A (en) * 1981-11-16 1983-06-28 Research Corporation Tuftsinyl-tuftsin
EP0253190B1 (de) * 1986-07-16 1992-12-30 ENIRICERCHE S.p.A. Teilweise retro-invertierte Analoge des Tuftsin, Methode zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten

Also Published As

Publication number Publication date
IT8919408A0 (it) 1989-02-10
JPH02215797A (ja) 1990-08-28
DE68917907D1 (de) 1994-10-06
EP0392095B1 (de) 1994-08-31
CA1338318C (en) 1996-05-07
ES2058473T3 (es) 1994-11-01
EP0392095A3 (de) 1991-01-30
DE68917907T2 (de) 1995-01-05
EP0392095A2 (de) 1990-10-17
US4957736A (en) 1990-09-18
IT1230712B (it) 1991-10-29

Similar Documents

Publication Publication Date Title
DK696988D0 (da) Nucleosider og nucleosidanaloge, farmaceutiske praeparater indeholdende disse forbindelser og fremgangsmaade til fremstilling af forbindelserne
DK38982A (da) Fremgangsmaade til fremstilling af 2-penemforbindelser
DE3881489T2 (de) Peptide mit collagenase hemmender wirkung.
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
DK0474712T3 (da) Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat
SE8604950D0 (sv) Dementia-improving and therapeutic agents
DE68917907T2 (de) Tuftsin-Analoge und Impfstoffe, die diese Analoge als Adjuvantien enthalten.
ZA9010067B (en) Novel 2-substituted 4-(3-alkyl-5-tert-butyl-4-hydroxyphenyl)thiazoles,processes for their preparation,pharmaceuticals containing them and their use
ATE116969T1 (de) Nmda-antagonisten.
DK0429370T3 (da) Hiditl ukendte thiophenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
MX9205365A (es) Imidazolilmetil-piridinas y composicion farmaceutica que las contiene.
MX9204457A (es) Compuestos de 6-oxo-azepinoidol, asi como procedimientos y productos intermedios para su preparacion, y medicamentos que contienen estos compuestos.
DK0508955T3 (da) Anvendelse af 2-iminothiazolidin-4-onderivater som nye lægemidler
ATE145911T1 (de) Inositol-phosphat-analog als kalzium- antagonistische substanz
ATE66145T1 (de) Pharmazeutische verwendung aromatischer thioaether.
HK1011863A1 (en) New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee